IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)
Ionis Pharmaceuticals (NASDAQ: IONS) shareholders saw their holdings slide after the Phase-3 CARDIO-TTRansform trial missed its primary endpoint -- and now have legal rights worth protecting. Levi & Korsinsky is investigating.
Shares of Ionis Pharmaceuticals fell more than 20% in the early trading on July 9, 2026, after the Company announced that its late-stage Phase-3 CARDIO-TTRansform trial, partnered with AstraZeneca, failed to meet its primary endpoint. If you purchased IONS securities and suffered a loss, you are encouraged to protect your shareholder rights now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
The CARDIO-TTRansform trial was designed to test whether the Company's therapy could reduce combined cardiovascular death and recurrent events in patients with transthyretin-mediated amyloid cardiomyopathy. On July 9, 2026, the Company disclosed the trial did not meet that primary endpoint. The share price abruptly declined after the news was released.
Levi & Korsinsky is investigating potential securities law violations on behalf of IONS investors. The investigation focuses on whether the Company adequately disclosed the risks tied to the CARDIO-TTRansform program prior to the July 9, 2026 readout. Shareholders retain important legal rights, and those rights are best preserved by acting promptly.
